103 related articles for article (PubMed ID: 38243079)
21. Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience.
Li Y; Sarkar FH
Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):11-7. PubMed ID: 26501150
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Nakazawa M; Antonarakis ES; Luo J
Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
[TBL] [Abstract][Full Text] [Related]
23. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
Li J; Hong Z; Zhang J; Zheng S; Wan F; Liu Z; Dai B
Oncogene; 2024 Mar; 43(10):744-757. PubMed ID: 38243079
[TBL] [Abstract][Full Text] [Related]
24. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
[TBL] [Abstract][Full Text] [Related]
25. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
[TBL] [Abstract][Full Text] [Related]
26. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
28. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
29. SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity.
Tang M; Chen G; Tu B; Hu Z; Huang Y; DuFort CC; Wan X; Mao Z; Liu Y; Zhu WG; Lu W
Sci Adv; 2023 Jun; 9(24):eade6624. PubMed ID: 37315132
[TBL] [Abstract][Full Text] [Related]
30. SMYD2 aggravates gastrointestinal stromal tumor via upregulation of EZH2 and downregulation of TET1.
Ji Y; Xu X; Long C; Wang J; Ding L; Zheng Z; Wu H; Yang L; Tao L; Gao F
Cell Death Discov; 2022 Jun; 8(1):274. PubMed ID: 35668081
[TBL] [Abstract][Full Text] [Related]
31. Boosting anticancer immunotherapy through androgen receptor blockade.
Pala L; De Pas T; Conforti F
Cancer Cell; 2022 May; 40(5):455-457. PubMed ID: 35537411
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Guan X; Polesso F; Wang C; Sehrawat A; Hawkins RM; Murray SE; Thomas GV; Caruso B; Thompson RF; Wood MA; Hipfinger C; Hammond SA; Graff JN; Xia Z; Moran AE
Nature; 2022 Jun; 606(7915):791-796. PubMed ID: 35322234
[TBL] [Abstract][Full Text] [Related]
33. Histone methyltransferase Smyd2 contributes to blood-brain barrier breakdown in stroke.
Wang J; Zhong W; Cheng Q; Xiao C; Xu J; Su Z; Su H; Liu X
Clin Transl Med; 2022 Mar; 12(3):e761. PubMed ID: 35297562
[TBL] [Abstract][Full Text] [Related]
34. SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth.
Yu YQ; Thonn V; Patankar JV; Thoma OM; Waldner M; Zielinska M; Bao LL; Gonzalez-Acera M; Wallmüller S; Engel FB; Stürzl M; Neurath MF; Liebing E; Becker C
Cell Death Dis; 2022 Jan; 13(1):52. PubMed ID: 35022391
[TBL] [Abstract][Full Text] [Related]
35. Cancer statistics, 2022.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
[TBL] [Abstract][Full Text] [Related]
36. SMYD2-mediated TRAF2 methylation promotes the NF-κB signaling pathways in inflammatory diseases.
Wu W; Wang J; Xiao C; Su Z; Su H; Zhong W; Mao J; Liu X; Zhu YZ
Clin Transl Med; 2021 Nov; 11(11):e591. PubMed ID: 34841684
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
